China: A Corporate/Commercial: Guangdong: Non-Contentious (PRC Firms) Overview

Shenzhen Stock Exchange Introduces Fourth ChiNext Listing Standard: Implications for High-Growth, R&D-Intensive Issuers

In April 2026, the Shenzhen Stock Exchange (SZSE) formally introduced the Fourth Listing Standard for the ChiNext Market. Unlike the first three listing standards, which are primarily profitability-driven, the new standard incorporates revenue growth and R&D intensity as core eligibility metrics. It is intended to accommodate innovative enterprises that typically feature substantial upfront investment, relatively low initial revenue and accelerated value creation.

For companies considering a ChiNext listing under this framework, compliance analysis should not be limited to financial metrics. Intellectual property, data compliance and civil and commercial dispute risks are likely to become key areas of regulatory focus in the listing review process.

Overview of the fourth listing standard

Pursuant to Article 2.1.2(4) of the Shenzhen Stock Exchange Rules Governing the Listing of Stocks on the ChiNext Market (2026 Revision), an issuer may qualify for listing by satisfying either of the following two sets of criteria.

• Route one – growth-oriented: (i) expected market capitalisation of not less than CNY3 billion; (ii) operating revenue for the most recent year of not less than CNY200 million; and (iii) compound annual revenue growth rate for the most recent three years of not less than 30%. This route is principally designed for issuers with established commercialisation capacity and a demonstrable growth trajectory, including companies in sectors such as new energy and emerging consumer businesses.
• Route two – innovation-oriented: (i) expected market capitalisation of not less than CNY4 billion; (ii) operating revenue for the most recent year of not less than CNY200 million; and (iii) aggregate R&D expenditure for the most recent three years of not less than CNY100 million, representing not less than 15% of aggregate operating revenue over the same period. This route is intended for issuers in frontier and strategically emerging sectors, including artificial intelligence, quantum technology and advanced biotechnology, where innovation capability is a primary driver of enterprise value.

In parallel, the SZSE has introduced related supervisory arrangements. These include a pre-filing consultation mechanism for IPO applicants to communicate with the exchange on sensitive issues prior to formal submission. In addition, for issuers that are not yet profitable at the time of listing, controlling shareholders and directors, supervisors and senior management are prohibited from reducing their shareholdings within three years after listing, and the issuer’s stock abbreviation will carry a “U” marker. These measures appear designed to balance greater market access with enhanced investor protection.

Intellectual property (IP): a core compliance and valuation issue

For issuers seeking to rely on the Fourth Listing Standard, IP is likely to be a central component of both valuation and regulatory scrutiny. In practice, IP compliance review should focus on at least three issues.

Chain of title and technology provenance

Many high-growth technology issuers have backgrounds involving university-industry collaboration, joint development or other research partnerships. As a result, the provenance of core technologies and the ownership of rights arising from collaborative R&D should be carefully examined. The issuer should be in a position to demonstrate that it possesses independent R&D capabilities and that no unresolved title issues exist that could constitute a material impediment to its continuing operations.

Mapping IP to products and revenue

Issuers should also be prepared to establish a clear link between patents, core products and revenue generation. This requires more than maintaining a large patent portfolio. Rather, the issuer should be able to show that its principal patents substantively cover its main product lines and proposed investment projects, and that the relevant IP supports, in a verifiable manner, the issuer’s commercial growth case.

Freedom to operate (FTO) and defensive preparedness

High-growth issuers may face targeted patent assertions or infringement allegations during the listing process, particularly from competitors. It is therefore prudent to conduct FTO analyses at an early stage of listing preparation and, where relevant, to extend the review to major overseas markets. A reactive approach to patent risk may be insufficient once filing is imminent or review is underway.

As a broader matter, issuers should avoid treating IP compliance as a formalistic legal exercise. Under the new listing framework, IP governance is increasingly relevant to both regulatory review and capital markets positioning.

Data compliance: general baselines and industry-specific requirements

Companies likely to qualify under the Fourth Listing Standard are often characterised not only by significant R&D expenditure and extended profit cycles, but also by intensive use of data and information assets. Data compliance is therefore likely to be another area of heightened scrutiny.

Baseline requirements

At a general level, issuers should be able to demonstrate compliance throughout the full life cycle of data and personal information processing. This includes, among other matters, lawful collection practices, de-identification or anonymisation measures where applicable, secure storage arrangements, and appropriate authorisation and consent mechanisms. Both governance frameworks and technical controls should be established in advance rather than retrofitted shortly before filing.

Sector-specific challenges

In addition to these baseline requirements, issuers may be subject to sector-specific obligations depending on their business model:

• artificial intelligence companies may need to address PRC requirements relating to algorithm filing, content governance and technology ethics;
• biopharmaceutical and life sciences companies may implicate special regulatory regimes, including those governing human genetic resources; and
• companies with cross-border operations or technical collaboration should pay particular attention to outbound data transfer issues, especially where overseas cloud services, cross-border R&D collaboration or foreign-hosted models are involved.

Cross-border data transfer remains a significant regulatory priority in China. Issuers should therefore assess carefully whether their operations trigger a Cyberspace Administration of China (CAC) security assessment, the filing of standard contractual clauses or other data export compliance requirements under applicable PRC rules.

Regulatory materiality

From a listing review perspective, data compliance issues are likely to converge on two principal questions: first, whether the issuer can clearly explain the source, ownership or control, permitted scope of use, and security safeguards relating to its key data assets; and second, whether any identified deficiencies could materially affect business continuity or give rise to risks that require specific disclosure.

Accordingly, data compliance should not be approached as a last-minute filing exercise. A staged and business-oriented compliance strategy is generally preferable.

Civil and commercial disputes: equity, contracts and corporate governance

Because many issuers targeted by the Fourth Listing Standard operate in rapidly evolving sectors and under relatively novel commercial models, they may be exposed to elevated civil and commercial dispute risks. In practice, three areas warrant particular attention.

Equity structure and shareholder arrangements

Cap tables in growth-stage companies are often complicated by multiple financing rounds, employee equity incentive arrangements, nominee holdings and valuation adjustment mechanisms (VAMs). Before filing, issuers should conduct focused legal due diligence to identify and unwind nominee arrangements, and to terminate, remove or otherwise regularise VAM clauses and similar arrangements where necessary. Unresolved equity disputes or structurally problematic shareholder arrangements are likely to attract regulatory inquiries.

Key commercial contracts

Material contracts – such as technology licensing agreements, long-term supply contracts and strategic co-operation arrangements – should be reviewed carefully for enforceability, performance status, termination risk and dispute exposure. Material defects in such agreements, or ambiguities in critical contractual terms, may lead to litigation or arbitration and, in serious cases, may be viewed as having a material adverse effect on the issuer’s ability to continue operations. Issuers should therefore maintain robust contract review procedures, ensure clarity in key terms and preserve sufficient evidence of performance.

Substantive corporate governance

Corporate governance issues remain a recurring area of attention in PRC listing reviews. Irregularities such as failure to perform approval procedures for related-party transactions, non-compliant convening of shareholders’ meetings or deficiencies in the approval of external guarantees may result in challenges to corporate resolutions or adverse regulatory comment. Issuers should accordingly strengthen their governance framework and enhance controls over higher-risk matters, particularly related-party transactions, external guarantees and other matters requiring heightened procedural discipline.

Conclusion

The Fourth ChiNext Listing Standard creates a new capital markets pathway for high-growth, R&D-intensive issuers that may not satisfy traditional profitability-based listing thresholds. At the same time, broader entry criteria should not be understood as a relaxation of regulatory review.

For prospective issuers, satisfying the financial and market capitalisation thresholds is only one part of the listing analysis. Equally important is the ability to demonstrate a sustainable and compliant operating foundation, particularly in relation to intellectual property ownership and defensibility, data compliance, and exposure to material civil and commercial disputes. Early and systematic legal preparation in these areas is likely to be critical to a successful listing under China’s registration-based IPO regime.

深交所第四套上市标准：新质生产力的资本市场入口与合规基石

2026年4月，创业板第四套上市标准落地。与此前侧重盈利导向的三套标准不同，此番改革将收入增速与研发投入强度纳入核心指标，精准回应了"前期投入大、收入起点低、价值跃升快"的创新创业企业的融资需求。

标准要点

根据《深圳证券交易所创业板股票上市规则（2026年修订）》第2.1.2条第（四）项，第四套标准设置两类指标，企业择一适用：

第一类：预计市值不低于30亿元，最近一年营业收入不低于2亿元，最近三年营收复合增长率不低于30%。这一路径突出成长性，适配已跑通商业模式的新能源、新型消费等企业。

第二类：预计市值不低于40亿元，最近一年营业收入不低于2亿元，最近三年累计研发投入不低于1亿元且占累计营收比例不低于15%。这一路径突出创新性，适配人工智能、量子科技、前沿生物技术等未来产业企业。

配套制度方面，深交所同步建立了IPO预先审阅机制，允许申报前就敏感信息前置沟通；首发未盈利企业控股股东及董监高三年内不得减持；未盈利企业股票简称加注"U"标识。这些安排兼顾了包容性与风险底线。

知识产权：从权属清晰到价值闭环

对于对标第四套标准的企业，知识产权是核心估值资产，合规诊断应聚焦三个维度：

首先是溯源式诊断。这类企业多具产学研融合背景，必须厘清核心技术来源与合作研发权属，确保企业具备独立于高校或合作方的研发能力，避免权属争议构成持续经营的实质性障碍。

其次是穿透式映射。企业需建立"专利—产品—收入"的清晰证据链，确保专利真实覆盖主营产品线及募投项目，防止无关专利充数，为成长性论证提供有力支撑。

最后是主动式防御。高成长企业常在申报期遭遇竞争对手的专利狙击，应在辅导期内前置完成FTO（自由实施分析），并将排查范围延伸至境外主要市场。

归根结底，企业须摒弃"重数量、轻质量"的惯性，将知识产权合规从法务职能提升为市值管理的战略基石。

数据合规：共性底线与个性挑战

符合第四套标准的企业，兼具科研投入大、利润周期长的经济特征和信息密集、数据密集的行业特征。

共性层面，企业须确保数据和个人信息处理的全生命周期合规，覆盖收集手段、脱敏技术、存储安全、授权匹配等各环节，提前布局制度与技术支撑。

个性层面，不同类型企业面临差异化要求。人工智能企业需应对算法备案及伦理问题，生物制药企业则可能触及人类遗传资源管理的特别规则。此外，数据出境是当前监管重心，涉及境外云服务、跨境协作或海外模型的企业，应审慎评估是否触发安全评估或标准合同备案义务。

从监管视角，数据合规问题最终聚焦两点：企业能否清晰说明数据资源的来源、权属、边界与安全控制；存在的缺陷是否足以影响业务持续性或构成必须披露的重大风险。拟申报企业不应将合规留待申报前突击，而应在发展过程中有重心地完成布局。

民商事争议：股权、合同与治理三条防线

第四套标准支持的企业因模式新颖、技术迭代快，面临股权、合同及公司治理等多重法律风险。

股权结构须清晰。多轮融资、员工持股计划及特殊股权安排容易滋生代持、对赌等问题，应在申报前专项核查，清理代持关系，终止或解除对赌条款，避免股权纠纷引发审核问询。

核心合同须合规。技术许可、长期供应等关键合同的履约瑕疵或条款分歧可能引发违约诉讼，甚至被认定为对持续经营能力构成重大不利影响。企业应健全合同审查机制，确保条款明确、履约留痕。

公司治理须实质化。关联交易未履行审议程序、股东会议召集不规范等瑕疵，可能触发公司决议纠纷。企业应完善治理机制，对关联交易、对外担保等高风险事项加强审查，防范审核中的负面评价。

结语

第四套标准为高成长、高研发投入企业开辟了资本市场新通道，但标准包容并不意味着审核放松。拟上市企业在对标财务指标之余，更应从知识产权、数据合规与民商事争议解决等维度开展系统性合规梳理，方能在注册制下行稳致远。